Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy

Hui Ding1, Xi Yang2, Yanzhang Wei3

  • 1Department of Biological Sciences, Clemson University, 190 Collings Street, Clemson, SC 29634, USA. ding4@clemson.edu.

Insights

Fusion proteins combining NKG2D (natural killer group 2, member D) and its ligands show promise for cancer immunotherapy by enhancing natural killer cell activity against tumors.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • NKG2D (natural killer group 2, member D) is a key activating receptor on NK cells and T cells.
  • NKG2D ligands (NKG2DLs) are frequently expressed on tumor cells, mediating target cell destruction upon engagement.
  • The NKG2D/NKG2DL axis presents a significant therapeutic target in cancer treatment.

Purpose of the Study:

  • To review recent advancements in the development of NKG2D/NKG2DL-based fusion proteins for cancer immunotherapy.
  • To highlight the potential of these fusion proteins in enhancing anti-tumor immune responses.

Main Methods:

  • Review of literature on fusion proteins incorporating NKG2D or its ligands.
  • Analysis of strategies involving antibodies, cytokines, and death receptors fused to NKG2D/NKG2DL.
  • Examination of NKG2D-based chimeric antigen receptors (CARs) as a therapeutic modality.

Main Results:

  • NKG2D/NKG2DL-based fusion proteins are emerging as a promising strategy in cancer immunotherapy.
  • These fusion proteins can be engineered by combining NKG2D or its ligands with other immune-modulating molecules.
  • NKG2D-based CARs represent a significant development in this field.

Conclusions:

  • Fusion proteins utilizing the NKG2D/NKG2DL interaction offer a potent approach for cancer immunotherapy.
  • Further development of these multi-functional fusion proteins holds significant therapeutic potential against various cancers.

Related Concept Videos

Tagging and Fusion Proteins01:24

Tagging and Fusion Proteins

Proteins are involved in several cellular processes and biochemical reactions. Analyzing a specific protein of interest requires it to be isolated from the other proteins in the cell. This is achieved by overexpressing the specific gene in a suitable host to produce large quantities of the target protein. A tag or label is recombined with the gene to produce a fusion protein containing the target protein and the tag. The tags on these fusion proteins can then be used for easy detection and...
8.5K
Nuclear Fusion02:45

Nuclear Fusion

The process of converting very light nuclei into heavier nuclei is also accompanied by the conversion of mass into large amounts of energy, a process called fusion. The principal source of energy in the sun is a net fusion reaction in which four hydrogen nuclei fuse and ultimately produce one helium nucleus and two positrons.
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
33.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
SNAREs and Membrane Fusion01:43

SNAREs and Membrane Fusion

Once a transport vesicle has recognized its target organelle, the vesicular membrane needs to fuse with the target membrane to unload the cargo. Transmembrane proteins called SNAREs present on organelle membranes and their vesicles, mediate vesicle fusion.
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...
12.9K
Fusion of Secretory Vesicles with the Plasma Membrane01:26

Fusion of Secretory Vesicles with the Plasma Membrane

Proteins and neurotransmitters in secretory vesicles can be released from a cell upon vesicle docking, priming, and fusion with the plasma membrane. Vesicles are docked and primed in preparation for the quick exocytosis of their contents in response to a stimulus. The fusion process is mainly carried out by a SNAP Receptor or SNARE complex, consisting of synaptobrevin, syntaxin-1, and SNAP-25.
In 1993, Jim Rothman proposed that the antiparallel pairing of vesicular and transmembrane SNAREs, or...
19.0K
Protein-protein Interfaces02:04

Protein-protein Interfaces

Many proteins form complexes to carry out their functions, making protein-protein interactions (PPIs) essential for an organism's survival. Most PPIs are stabilized by numerous weak noncovalent chemical forces. The physical shape of the interfaces determines the way two proteins interact. Many globular proteins have closely-matching shapes on their surfaces, which form a large number of weak bonds. Additionally, many PPIs occur between two helices or between a surface cleft and a...
14.8K